Cost and Cost-Effectiveness of an Early Invasive vs Conservative Strategy for the Treatment of Unstable Angina and Non ST-Segment Elevation Myocardial Infarction - Cost and Cost-Effectiveness of an Early Invasive vs Conservative Strategy for the Treatment of Unstable Angina and Non ST-Segment Elevation Myocardial Infarction

Description:

The authors sought to examine total 6-month costs and long-term cost-effectiveness of an invasive vs a conservative strategy in the management of patients with either unstable angina or non ST-segment elevation myocardial infarction (UA/NSTEMI) treated with the platelet glycoprotein (Gp IIb/IIIa) inhibitor tirofiban.